Opioid-induced Constipation
📧 Sign up to get email alerts when something new happens for Opioid-induced Constipation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) [Phase 2]
Phase 2 dose-ranging study completed assessing SP-333 for opioid-induced constipation (OIC), evaluating safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation [Phase 2]
A Phase 2 clinical trial assessing safety, tolerability, and activity of TD-1211 in patients with opioid-induced constipation has completed.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation [Phase 2]
Phase 2 clinical trial completed evaluating safety and efficacy of TD-1211 for opioid-induced constipation in adults.
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation [Phase 1, Phase 2]
A multiple-dose clinical trial update for TD-1211 evaluating safety and pharmacology in healthy volunteers and patients with opioid-induced …
-
FDA approval · 2020-11-30FDA Approved: LUBIPROSTONE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
The FDA approved a supplemental application for Lubiprostone submitted by Dr. Reddy's Laboratories, updating labeling under NDA 021908.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain [Phase 2]
Phase 2 clinical trial evaluating oral MOA-728 for treating opioid-induced bowel dysfunction in adults with chronic non-malignant pain; resu…
-
FDA approval · 2020-04-13FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
The FDA approved a supplemental application for Movantik (naloxegol oxalate) submitted by RedHill Biopharma Ltd.
-
CLINICAL_TRIALS withdrawal · 2019-11-29Clinical Trial Update: Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects [Phase 4]
A Phase 4 clinical trial evaluating subcutaneous methylnaltrexone for opioid-induced constipation in cancer patients has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain [Phase 2]
Phase 2 trial evaluating oral MOA-728 for opioid-induced bowel dysfunction in chronic non-malignant pain was completed.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain [Phase 3]
Phase 3 trial evaluating oral methylnaltrexone (MNTX) for treating opioid-induced constipation in adults with chronic non-malignant pain has…
-
CLINICAL_TRIALS trial_result · 2019-09-04Clinical Trial Update: Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures [Phase 2]
Phase 2 clinical trial evaluating subcutaneous methylnaltrexone for opioid-induced constipation during rehabilitation after orthopedic surge…
-
CLINICAL_TRIALS trial_result · 2019-09-04Clinical Trial Update: Compassionate Use Study of Methylnaltrexone [NA]
Compassionate use study of methylnaltrexone for opioid-induced constipation has completed with results posted.
-
FDA label_change · 2019-05-29FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
FDA approved a supplemental application for MOVANTIK (naloxegol oxalate) submitted by RedHill Biopharma Ltd, primarily affecting labeling ch…
-
CLINICAL_TRIALS trial_result · 2019-04-08Clinical Trial Update: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain [Phase 2]
Phase 2 randomized trial evaluating linaclotide for opioid-induced constipation in patients on chronic opioid therapy for non-cancer pain ha…
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy [Phase 4]
Phase 4 clinical trial comparing oxycodone/naloxone with oxycodone after laparoscopic hysterectomy for postoperative pain and opioid-induced…
-
CLINICAL_TRIALS trial_result · 2018-09-28Clinical Trial Update: Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation [Phase 3]
Phase 3 clinical trial update for Naloxone HCl PR tablets targeting opioid-induced constipation.
-
CLINICAL_TRIALS trial_result · 2018-07-13Clinical Trial Update: To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation [Phase 4]
Phase 4 trial comparing patient preference between Movantik (naloxegol) and polyethylene glycol 3350 for opioid-induced constipation; result…
-
CLINICAL_TRIALS trial_result · 2018-05-22Clinical Trial Update: Use of MgSO4 for Pain After Bariatric Surgery [NA]
Completed clinical trial evaluating magnesium sulfate for pain relief after bariatric surgery, with the study related to opioid-induced cons…
-
FDA approval · 2018-04-26FDA Approved: LUBIPROSTONE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Lubiprostone filed by Dr. Reddy's Laboratories Inc.
-
FDA label_change · 2018-03-14FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Relistor (methylnaltrexone bromide) from Salix Pharmaceuticals to update its labeling.
-
FDA approval · 2018-03-14FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
FDA approved a supplemental application for Relistor (methylnaltrexone bromide) from Salix Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness [Phase 4]
This document reports results from a Phase 4 study of subcutaneous methylnaltrexone for opioid-induced constipation in patients with advance…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness [Phase 4]
A Phase 4 safety evaluation of subcutaneous methylnaltrexone for opioid-induced constipation in patients with advanced illness has completed…
-
FDA approval · 2018-02-28FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
FDA approved a supplemental application for MOVANTIK (naloxegol oxalate) filed by RedHill Biopharma Ltd.
-
FDA approval · 2018-01-24FDA Approved: SYMPROIC — Supplemental Application (BioDelivery Sciences International Inc)
FDA approved a supplemental application for Symproic (nalmefene) submitted by BioDelivery Sciences International Inc.